Impact of Whole Body Vibration on Sleep Symptoms and the Brain in Obstructive Sleep Apnea
Whole Body Vibration
Apnea+6
+ Nervous System Diseases
+ Respiration Disorders
Treatment Study
Summary
Study start date: April 1, 2020
Actual date on which the first participant was enrolled.OSA subjects will be recruited from the UCLA Sleep Disorders Center via recruitment flyers. When prospective subjects contact the study coordinator, the study will be explained in greater detail, and inclusion and exclusion criteria reviewed. If the person agrees to participate, appointments for data collection will be made and copies of the informed consent will be mailed for their review for at least 3 days before the study. Then the Project Coordinator or one of the PI's will contact the prospective subject, answer any questions about the study, and obtain signed, informed consent. Baseline measures (PSQI, BDI-II, height, weight, vital signs \[temperature, heart rate, blood pressure\]) will be obtained. At 6 weeks, baseline measures will be repeated and an overnight polysomnography study will be performed at the subject's home. All subjects will be given the WBV device at the end of the study. Delivery of the WBV device to each subject's home will be arranged and the WBV device and pedometer set up by the research team. Training in the use of the WBV device will be provided inperson and via written instructions. Phone and e-mail support for the WBV device or any study questions will be available for all study participants. Subjects will use the device at least 3 times/week, for 30 minutes per session, for 6 weeks. In addition to the pedometer, a wall calendar will be provided on which subjects will mark the days that they use the WBV device. Project Coordinator will visit subjects weekly, and as needed, to record pedometer readings, check wall calendar for WBV device use, and to answer any subjects' questions or concerns. Brain MRI scans will be performed at baseline and after 6 weeks. An MRI-compatible pulse oximeter, and an air-filled pressure transducer will be connected to the subject to monitor heart rate, O2 saturation, and thoracic wall movement, and then the subject will be positioned in the scanner for data collection.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 40 to 65 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: * AHI ≥15 * new diagnosis of moderate to severe OSA (via overnight polysomnography) * and able to lay flat (requirement for brain MRI) * must have space and electrical power access for WBV device at their home Exclusion Criteria: * other forms of sleep-disordered breathing (such as central sleep apnea, restless legs syndrome, mixed sleep apnea) * currently using (or will start using during 6-week study period) CPAP or BiPAP or oral appliance for OSA treatment * recent (\<6 months) myocardial infarction * current pregnancy (if subject is female) * history of stroke * diagnosed psychiatric disease (schizophrenia, manic-depressive) * airway or chest deformities that would interfere with breathing * mechanical ventilatory support * renal failure (requiring dialysis) For brain MRI * claustrophobia * metallic-based tattoos * metallic implants or devices (such as implantable cardioverter-defibrillator, pacemaker, embolic coils, aneurysm clips) or any other material that could be hazardous in MRI scanner * body weight \>300 lbs (restrictions of MRI scanner table)
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Objectives
Primary Objectives
Secondary Objectives